Core Insights - Phio Pharmaceuticals is set to present clinical data from its ongoing Phase 1b trial of siRNA-based INTASYL PH-762 for skin cancer at the 40th Annual Meeting of the Society for Immunotherapy of Cancer [1][2] Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology aimed at eliminating cancer [1][4] - The company's lead clinical program, PH-762, targets the PD-1 gene, which is implicated in various forms of skin cancer, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [4] Clinical Trial Details - The ongoing Phase 1b clinical trial is designed to evaluate the safety and tolerability of intratumoral injection of PH-762 in patients with specific skin cancers [2][4] - The trial is registered under NCT 06014086 and aims to assess PH-762 as a potential non-surgical treatment option for skin cancers [4] Presentation Information - The poster presentation titled "PD-1 Directed Intratumoral Immunotherapy for Cutaneous Carcinomas: A Clinical Study of INTASYL PH-762" will be presented by Mary Spellman, M.D. on November 8, 2025 [3]

Core Insights - Phio Pharmaceuticals' INTASYL compound PH-762 has been awarded the 2025 Immunomodulatory Solution of the Year by the BioTech Breakthrough Awards Program, highlighting its significance in cancer treatment [1][2][3] Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology aimed at eliminating cancer [1][4] - The company's lead clinical program, PH-762, targets the PD-1 gene associated with various skin cancers and is currently undergoing a Phase 1b trial for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [4] Industry Recognition - The BioTech Breakthrough Awards program is an independent initiative that recognizes outstanding achievements in life sciences and biotechnology globally, with a focus on innovative solutions and products [2][9] - The award received by PH-762 underscores its potential as a non-surgical treatment option for patients with cutaneous carcinomas, addressing a significant medical need [3]

Core Viewpoint - Phio Pharmaceuticals has received a positive recommendation from the Safety Monitoring Committee to advance its clinical trial for PH-762, a siRNA compound targeting skin cancer, to the fifth dose escalation cohort, indicating a supportive safety profile through the fourth cohort [1][6]. Group 1: Clinical Trial Progress - The Phase 1b clinical trial (NCT 06014086) has enrolled five patients in the fourth cohort, with four diagnosed with cutaneous squamous cell carcinoma (cSCC) and one with Merkel cell carcinoma, all of whom tolerated the injections well without serious adverse events [2][4]. - A total of 15 patients have been treated across the first four cohorts, including 13 with cSCC, one with metastatic melanoma, and one with Merkel cell carcinoma [4]. - The company anticipates completing enrollment in the final cohort by the third quarter of 2025 [6]. Group 2: Efficacy and Safety Profile - Pathological responses at Day 36 showed a complete response (100% tumor clearance) in 4 out of 9 patients with cSCC, with one patient showing near complete response (>90% clearance) and another showing partial response (>50% clearance) [5]. - No patients exhibited clinical progression of disease, and the continuing favorable safety profile of PH-762 suggests it may be a well-tolerated treatment option for skin cancer [6][3]. Group 3: Company Overview - Phio Pharmaceuticals is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology, particularly in the field of immuno-oncology [7][8]. - PH-762 is designed to silence the PD-1 gene, which is implicated in various forms of skin cancer, and represents a potential non-surgical treatment option [8].